 |
|
|
| |
A Fixed-Dose Combination of Sofosbuvir and Ledipasvir Is Highly Effective in Treatment-Naïve and Treatment-Experienced Genotype 1 HCV-Infected Patients: Results From the LONESTAR and ELECTRON Phase 2 Studies - poster
|
| |
| |
Reported by Jules Levin
HEP DART 2013, December 8-12, 2013, Big Island, HI, USA
AASLD: Gilead at AASLD: Sofosbuvir for GT 3, 2 and 1 - (11/18/13)
AASLD: Gilead at AASLD: 2 - (11/18/13)
AASLD: Summary from AASLD 2013 for Hepatitis C Washington 1-5 November 2013 - Written by Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany - (12/02/13)
AASLD: BMS at AASLD - (11/18/13)
64rd Annual Meeting of the American Association for the Study of Liver Diseases
Washington, DC Nov 1-5 2013
Eric Lawitz,1,2 Catherine Stedman,3 Fred F. Poordad,1,2 Phillip S. Pang,4 Xiao Ding,4 Robert H. Hyland,4 William T. Symonds,4 Fernando E. Membreno,1,2 Edward Gane5
1Texas Liver Institute, San Antonio, TX; 2University of Texas Health Science Center, San Antonio, TX; 3Christchurch Clinical Studies Trust, Christchurch, New Zealand; 4Gilead Sciences, Inc., Foster City, CA; 5Auckland Clinical Studies, Auckland, New Zealand
|
| |
|
|
|
|
|
